Tafenoquine is an analogue of primaquine with an improved therapeutic and safety profile. It has a long half-life and activity against liver-stage malaria parasites, so may be useful for chemoprophylaxis. Antimalarial agents are drugs used for the treatment or prophylaxis of malaria. Malaria is caused by four species of Plasmodium, such as Plasmodium falciparum, P. malariae, P. ovale, and P. vivax. Arakoda contains tafenoquine succinate, an antimalarial agent for oral administration. The molecular formula of tafenoquine succinate is C24H28F3N3O3·C4H6O4 and its molecular weight is 581.6 as the succinate salt. It is given in prophylaxis of malaria patient aged 18 years older. Tafenoquine is active against pre-erythrocytic (liver) and erythrocytic (asexual) forms as well as gametocytes of Plasmodium species. G6PD test is performed before giving the drug. Analytical studies were on NMR, IR, MS, HPLC, Flourimetry analysis. In vitro studies have shown that tafenoquine presents an average 50% inhibitory concentration of 0.436mcg against blood stages of seven strains of P. falciparum. The long-acting 8-aminoquinoline tafenoquine (TQ) co-administered with chloroquine (CQ) may radically cure Plasmodium vivax malaria. Coadministration therapy was evaluated for a pharmacokinetic interaction and for pharmacodynamic, safety and tolerability characteristics. Volume of distribution. The activation of tafenoquine needs the activity of CYP 2D6 liver microsomal enzyme. Routes of elimination are through feces.
Cite this article:
Syeda Sana, Mohsina Abed. Review on Arakoda (Tafenoquine) and its approach as an Anti-Malarial Agent. Research Journal of Pharmacy and Technology. 2021; 14(4):2336-0. doi: 10.52711/0974-360X.2021.00412
Syeda Sana, Mohsina Abed. Review on Arakoda (Tafenoquine) and its approach as an Anti-Malarial Agent. Research Journal of Pharmacy and Technology. 2021; 14(4):2336-0. doi: 10.52711/0974-360X.2021.00412 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2021-14-4-88
1. Peters W (1999). "The evolution of tafenoquine--antimalarial for a new millennium?". J R Soc Med. 92 (7): 345–52. doi:10.1177/014107689909200705. PMC 1297286. PMID
2. Haston JC, Hwang J, Tan KR (November 2019). "Guidance for Using Tafenoquine for Prevention and Antirelapse Therapy for Malaria — United States, 2019"(PDF). MMWR. Morbidity and Mortality Weekly Report. 68 (46): 1062–1068. doi:10.15585/mmwr.mm6846a4. PMID
3. "Tafenoquine Succinate (Krintafel) Monograph for Professionals". Drugs.com. Retrieved 22 November 2019.
4. Hounkpatin, Aurore B; Kreidenweiss, Andrea; Held, Jana (March 2019). "Clinical utility of tafenoquine in the prevention of relapse of Plasmodium vivax malaria: a review on the mode of action and emerging trial data". Infection and Drug Resistance. Volume 12: 553–570. doi:10.2147/IDR.S151031.
5. "Krintafel Prices, Coupons and Patient Assistance Programs". Drugs.com. Retrieved 22 November 2019.
6. "Tafenoquine Approved for Malaria Prophylaxis and Treatment". Centers for Disease Control and Prevention (CDC). 25 April 2019. Retrieved 22 November 2019.